The company’s lead candidate is M2SR—a live, single-replication, intranasal flu vaccine based on an invention by UW Madison virologists and FluGen co-founders Yoshihiro Kawaoka, PhD, and Gabriele Neumann PhD. In an unprecedented challenge trial, M2SR demonstrated protection against infection and illness across seven years of virus drift and induced a durable antibody response with the potential to cover an entire flu season and beyond . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge